All this stock is trading on since at least June has been technicals. There's been no solid news one way or the other, so we're at the mercy of the charts, plus the odd attempt at manipulation from shorts or enthusiasts. But what else can we expect, this is a story stock with no operating results to base a valuation judgement on.
Reminds me of a friend who traded for a mutual funds in the Czech Republic. They have no decent reporting requirements there, so I asked how he decided what to buy. Strictly technicals, he said. They had charting software, bought and sold all day long stocks of companies that were essentially black boxes, and made 30% annually (until the market crashed).
The nearest scheduled news is the Xopenex trial designed to demonstrate deleterious effects from the inactive isomer. I've been dreading this, for if the results are bad, it would mean the skeptics are right, and all we've got is generic albuterol. Pleased to see from Peter's post and the similar post at YC, that we may have positive results from this trial. That may well be the driver to move us to the next level. And, of course, any number of collaborations could put us over 100 in a matter of days as well.
Good weekend all, let's not worry about SEPR until Monday--we're unchanged on the week.
|
